Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by mineoneon Dec 20, 2007 10:33pm
355 Views
Post# 14056327

from Casey energy speculator

from Casey energy speculator Dec. 17, 2007 The Ghost of Christmas Future For the uranium stocks, we predict 2008 will be the year of consolidations. We will see a few of the top juniors join together, then get bought out by larger companies. A prime example is our new company recommendation: Blue Rock Resources (V.BRD, see below for details). In our opinion, a combination/merger with Magnum Uranium (V.MM, another CES recommendation) would make the best junior emerging producer in the United States, with major exploration upside. We also see Ur-Energy (T.URE), because they are flush with cash, possibly buying out both Blue Rock and Magnum to make by far the best near-term producer in the United States. The optimal situation for us is if Denison buys out all three companies, thus becoming without a doubt the most dominating uranium producer in North America next to Cameco mineone
Bullboard Posts